A New Biologic Medicine for Multiple Sclerosis
A Novel Immunological-Directed Synthetic Biology-Based Drug for the Treatment of Multiple Sclerosis
['FUNDING_SBIR_2'] · RISE THERAPEUTICS, LLC · NIH-11142450
This project aims to create a new type of medicine using the body's natural systems to help people with Multiple Sclerosis.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | RISE THERAPEUTICS, LLC (nih funded) |
| Locations | 1 site (Rockville, UNITED STATES) |
| Trial ID | NIH-11142450 on ClinicalTrials.gov |
What this research studies
Multiple Sclerosis (MS) is a serious condition where the immune system attacks the protective covering of nerves, leading to various symptoms and complications. This project is developing a novel medicine that uses synthetic biology to guide the immune system. It focuses on the connection between the gut and the brain, aiming to use a special probiotic to help restore balance to the immune system. The goal is to control immune cells in the gut to reduce the harmful immune response seen in MS, potentially preventing further damage.
Who could benefit from this research
Good fit: Patients living with Multiple Sclerosis who experience an overactive immune response and related symptoms may be ideal candidates for future applications of this therapeutic.
Not a fit: Patients without Multiple Sclerosis or those whose condition is not primarily driven by the specific immune dysregulation targeted by this approach may not receive benefit.
Why it matters
Potential benefit: If successful, this new medicine could offer a cutting-edge way to treat Multiple Sclerosis by rebalancing the immune system and potentially reducing disease severity and complications.
How similar studies have performed: While the specific approach is novel, previous work has shown that probiotics can improve MS severity by increasing anti-inflammatory cells, supporting the important role of the gut-brain axis.
Where this research is happening
Rockville, UNITED STATES
- RISE THERAPEUTICS, LLC — Rockville, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: FURLAN FREGUIA, CHRISTIAN — RISE THERAPEUTICS, LLC
- Study coordinator: FURLAN FREGUIA, CHRISTIAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Autoimmune Diseases